Abstract

GBS stands as a unique autoimmune disease which prompts the body’s immunity system to attack peripheral nervous system structures resulting in swift deteriorating muscle weakness coupled with total loss of reflexes and extreme cases lead to respiratory failure. The precise causes of GBS remain unknown although the majority of GBS cases begin following infections by Campylobacter jejuni, influenza and the Zika virus and rarely by vaccines and surgical procedures. Precise categories of Guillain-Barre syndrome include Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) and Acute Motor Axonal Neuropathy (AMAN) and Miller Fisher Syndrome (MFS). These subtypes show different patterns of nervous system damage. The combination of clinical features with cerebrospinal fluid tests showing albuminocytologic dissociation, nerve conduction studies serves to diagnose the condition. Protocols for management consist of immunotherapy applications combined with plasma exchange and intravenous immunoglobulin therapy which support patients through respiratory failure complications along with autonomic instability manifestations. Patients normally recover within six to twelve months of diagnosis yet some patients face persistent deficits along with persistent symptoms including fatigue and neuropathic pain. The patients’ expected outcomes are determined by their age at diagnosis together with their disease pronunciation and when they began treatment. Research today prioritizes discovering disease mechanisms while finding biomarkers alongside therapeutic strategy development. Progress in GBS care has cut the mortality rate and decreased long-term disabilities but ongoing clinical research needs to push forward both treatment quality and patient care outcomes. This review demonstrates why healthcare professionals must actively raise awareness and immediately react to this complex condition while scientists must intensify their research into its ongoing challenges.

• 1.   Willison, H.J., Jacobs B.C., van Doorn P.A. Guillain-Barré syndrome. The Lancet. 2016; 388(10045): 717-727.
• 2.   Yuki N., Hartung, H.P. Guillain-Barré syndrome. New England Journal of Medicine. 2012; 366(24): 2294-2304.
• 3.   Sejvar J.J., Baughman A.L., Wise M., Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and metaanalysis. Neuroepidemiology. 2011; 36(2): 123-133.
• 4.   Bellanti R., Rinaldi S. Guillain-Barré syndrome: a comprehensive review. Eur J Neurol. 2024; 31: e16365.
• 5.   Khan S.A., Das P.R., Nahar Z., Dewan S.M.R. An updated review on Guillain-Barré syndrome: Challenges in infection prevention and control in low and middle-income countries. SAGE Open Medicine. 2024; 12: 1–8.
• 6.   Leonhard S.E., Mandarakas M.R., Gondim FAA, Bateman K et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology. 2019; 15: 671-683.
• 7.   Abuawwad T.M., Taha M.J.J., Taha A.J., Kozaa Y.A., Falah O., Abuawwad T.I., Hammad E.M., Mahmoud A.A., Aladawi A., Serhan HA. Guillain-Barr´e syndrome after COVID-19 vaccination: A systematic review and analysis of case reports. Clinical Neurology and Neurosurgery. 2024; 238: 108183.
• 8.   Winer J.B. Guillain-Barré syndrome. B.M.J. 2008; 337: a671.
• 9.   Esposito S., Longo M.R. Guillain–Barré syndrome. Autoimmunity Reviews. 2017; 16: 96–101.

Data Sharing Statement

Funding